PubMed Health⌕ Search

Biomedical subjects

D Jährig

Publications and source records attributed to D Jährig.

36 records · Page 2Linked to original sources
PubMed1982

Dependence of the efficiency of phototherapy on plasma bilirubin concentration.

407 newborns with idiopathic transitory hyperbilirubinaemia were examined with regard to the decrease in serum bilirubin levels during 24 hours of intermittent phototherapy (12 hours of light exposure). The photoeffect (i.e. decrease of serum bilirubin concentration after 24 hours of therapy) showed a unique and predictable nonlinear correlation with the plasma bilirubin concentration before treatment. This relationship can be used for individualizing the duration of phototherapy and the dose of light. The apparent effect of birth weight, gestational age, and postnatal age on the efficiency of phototreatment is only due to differing initial levels of bilirubin concentration. Intermittent illumination seemed to be more efficient than continuous.

Bilirubin↗
PubMed1981

[Photodynamic injuries of erythrocytes during illumination with blue light in patients with icterus neonatorum].

In a prospective study the influence of intermittent phototherapy (with and without riboflavin substitution) on red blood cells of newborns was examined in vivo. Hemoglobin concentration and hematocrit values did not differ significantly between treated patients and untreated controls. However, after illumination during 24 h (real exposure time 12 h) with a highly effective NC 400-04 Narva lamp, we found a completely reversible decrease of the mean erythrocyte diameters. The changes were statistically significant at the 8th day of life and disappeared up to the 16th day after birth. Riboflavin administration immediately before starting the phototherapy was able to prevent this phenomenon. The glutathione reductase activity (method by BEUTLER) was not affected, neither by phototherapy alone nor by riboflavin administered additively. As a conclusion of our results we would like to recommend a general riboflavin substitution in newborns after phototreatment.

Erythroblastosis, Fetal↗
PubMed1980

Kinetics of self-sensitized and riboflavin-sensitized photodegradation of bilirubin.

Kinetics of self-sensitized or riboflavin-sensitized photodestruction of bilirubin in albumin containing solutions follows equations of the Stern-Volmer type, which resemble expressions of enzyme catalyzed reactions. The dependence of quantum yields of bilirubin decay on substrate concentration, bilirubin/albumin ratio, and riboflavin concentration is estimated and described in terms of such equations. The ratios of kinetic constants obtained in this way are discussed and related to clinical experiences regarding the phototherapy for the treatment of neonatal hyperbilirubinaemia.

Bilirubin↗
PubMed1978

[Determination of residual bilirubin binding capacity in the serum of newborn infants using bromphenol blue].

In serum specimens collected from premature infants the residual bilirubin binding capacity was determined by a direct spectrometric method using bromphenol blue. The bindingin capacity determined in this way is strongly correlated to the serum bilirubin level. Changes in binding capacity are shown during the first 16 days of life. Experiments on model sera show the dependence of binding capacity for bromphenol blue on the ratio albumin/bilirubin. The results are discussed with respect to the urgency of blood exchange transfusions preventing danger of kernicterus.

Bilirubin↗
PubMed1978

Photodegradation of bilirubin as enhanced by photosensitizers in vitro.

Photosensitizers such as methylene blue or riboflavin enhance the rate of bilirubin photodegradation in vitro. This effect is studied with respect to dose-response and time-response relationships, the influence of concentrations of bilirubin and albumin, and the oxygen consumption. The results are discussed in view of the probability that the effects described also occur in vivo and that riboflavin supplementation to neonates could improve the phototherapy of neonatal hyperbilirubinaemia.

Bilirubin↗
PubMedDate not supplied

[Risk groups of newborn infants of diabetic mothers in relation to their somatic outcome and maternal diabetic metabolic status in pregnancy].

In a prospective study, neonatal morbidity of newborn children of diabetic mothers and its association with the maternal metabolism was determined. Particular attention was directed on the somatic outcome of the children and their frequent metabolic imbalances. In addition, we determined the influence of maternal biological and somatometrical variables on the somatic outcome of newborns. Dependent upon the mothers' and children' variables, risk groups of newborns (fetopathy groups) were defined to optimize clinical care and surveillance of newborns. A total of 810 children were included born to mothers with primary insulin dependent diabetes mellitus (IDDM), non insulin dependent diabetes (NIDDM), or gestational diabetes (GDM). Among the study population, 41.7% of children had macrosomia, 27.2% had a weight-length index > 1.2, 17.9% developed hypoglycemia and 19.5% hyperbilirubinemia within the initial 72 hours after birth. The somatic outcome of the children was significantly associated with pregnancy duration, maternal age, weight, height, and HbA1. Increasing maternal HbA1 prior to delivery (categorized in < 8.5%, 8.6-10%, > 10%) was associated with increased relative risk of incidence of neonatal morbidity. Finally, risk groups (fetopathy groups I-III) were defined according to maternal HbA1 value and somatic outcome of the newborns. The importance of these fetopathy groups for criteria of neonatal morbidity is demonstrated. Based upon categorization of newborn children into fetopathy groups, children should be allocated to specific concepts of appropriate surveillance and clinical care. The fetopathy classification may also serve as an independent tool for retrospective quality control of diabetic pregnancy.

Adult↗